Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Core Insights - Clearmind Medicine Inc. has announced the publication of a U.S. patent application for a combination therapy involving 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, targeting binge behavior disorders [1][2] - The therapy aims to address various binge behaviors, including excessive alcohol consumption, binge eating, smoking, compulsive shopping, and problematic sexual conduct, by leveraging MEAI's neuroplastic properties [2][3] - The company has filed a total of 13 patents related to its collaboration with SciSparc Ltd., focusing on conditions such as alcohol use disorder, cocaine addiction, obesity, and depression [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder [5] - The company's intellectual property portfolio includes 19 patent families and 31 granted patents, with plans to seek additional patents as warranted [6] Strategic Goals - The CEO of Clearmind emphasized the company's mission to pioneer safe and effective treatments for binge behaviors, aiming to meet unmet needs in addiction medicine [4][8] - The combination of MEAI and PEA is positioned as a potentially safer and more effective treatment option compared to existing therapies [2][4]